
Global Multivalent Oral Rotavirus Vaccine Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Multivalent Oral Rotavirus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Multivalent Oral Rotavirus Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Multivalent Oral Rotavirus Vaccine market include Serum Institute of India, Lanzhou Institute of Biological Products and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Multivalent Oral Rotavirus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Multivalent Oral Rotavirus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Oral Rotavirus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multivalent Oral Rotavirus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Multivalent Oral Rotavirus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Multivalent Oral Rotavirus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Multivalent Oral Rotavirus Vaccine Segment by Company
Serum Institute of India
Lanzhou Institute of Biological Products
Merck
Multivalent Oral Rotavirus Vaccine Segment by Type
RV3
RV5
Multivalent Oral Rotavirus Vaccine Segment by Application
Government Institution
Private Sector
Other
Multivalent Oral Rotavirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Multivalent Oral Rotavirus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Multivalent Oral Rotavirus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Multivalent Oral Rotavirus Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Multivalent Oral Rotavirus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Oral Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Oral Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Oral Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Multivalent Oral Rotavirus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multivalent Oral Rotavirus Vaccine industry.
Chapter 3: Detailed analysis of Multivalent Oral Rotavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Multivalent Oral Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Multivalent Oral Rotavirus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Multivalent Oral Rotavirus Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Multivalent Oral Rotavirus Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Multivalent Oral Rotavirus Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Multivalent Oral Rotavirus Vaccine market include Serum Institute of India, Lanzhou Institute of Biological Products and Merck, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Multivalent Oral Rotavirus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Multivalent Oral Rotavirus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Multivalent Oral Rotavirus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Multivalent Oral Rotavirus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Multivalent Oral Rotavirus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Multivalent Oral Rotavirus Vaccine sales, projected growth trends, production technology, application and end-user industry.
Multivalent Oral Rotavirus Vaccine Segment by Company
Serum Institute of India
Lanzhou Institute of Biological Products
Merck
Multivalent Oral Rotavirus Vaccine Segment by Type
RV3
RV5
Multivalent Oral Rotavirus Vaccine Segment by Application
Government Institution
Private Sector
Other
Multivalent Oral Rotavirus Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Multivalent Oral Rotavirus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Multivalent Oral Rotavirus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Multivalent Oral Rotavirus Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Multivalent Oral Rotavirus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multivalent Oral Rotavirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Multivalent Oral Rotavirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multivalent Oral Rotavirus Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Multivalent Oral Rotavirus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Multivalent Oral Rotavirus Vaccine industry.
Chapter 3: Detailed analysis of Multivalent Oral Rotavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Multivalent Oral Rotavirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Multivalent Oral Rotavirus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
194 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 1.2.2 Global Multivalent Oral Rotavirus Vaccine Sales Volume (2020-2031)
- 1.2.3 Global Multivalent Oral Rotavirus Vaccine Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Multivalent Oral Rotavirus Vaccine Market Dynamics
- 2.1 Multivalent Oral Rotavirus Vaccine Industry Trends
- 2.2 Multivalent Oral Rotavirus Vaccine Industry Drivers
- 2.3 Multivalent Oral Rotavirus Vaccine Industry Opportunities and Challenges
- 2.4 Multivalent Oral Rotavirus Vaccine Industry Restraints
- 3 Multivalent Oral Rotavirus Vaccine Market by Company
- 3.1 Global Multivalent Oral Rotavirus Vaccine Company Revenue Ranking in 2024
- 3.2 Global Multivalent Oral Rotavirus Vaccine Revenue by Company (2020-2025)
- 3.3 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Company (2020-2025)
- 3.4 Global Multivalent Oral Rotavirus Vaccine Average Price by Company (2020-2025)
- 3.5 Global Multivalent Oral Rotavirus Vaccine Company Ranking (2023-2025)
- 3.6 Global Multivalent Oral Rotavirus Vaccine Company Manufacturing Base and Headquarters
- 3.7 Global Multivalent Oral Rotavirus Vaccine Company Product Type and Application
- 3.8 Global Multivalent Oral Rotavirus Vaccine Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Multivalent Oral Rotavirus Vaccine Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Multivalent Oral Rotavirus Vaccine Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Multivalent Oral Rotavirus Vaccine Market by Type
- 4.1 Multivalent Oral Rotavirus Vaccine Type Introduction
- 4.1.1 RV3
- 4.1.2 RV5
- 4.2 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Type
- 4.2.1 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Type (2020-2031)
- 4.2.3 Global Multivalent Oral Rotavirus Vaccine Sales Volume Share by Type (2020-2031)
- 4.3 Global Multivalent Oral Rotavirus Vaccine Sales Value by Type
- 4.3.1 Global Multivalent Oral Rotavirus Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Multivalent Oral Rotavirus Vaccine Sales Value by Type (2020-2031)
- 4.3.3 Global Multivalent Oral Rotavirus Vaccine Sales Value Share by Type (2020-2031)
- 5 Multivalent Oral Rotavirus Vaccine Market by Application
- 5.1 Multivalent Oral Rotavirus Vaccine Application Introduction
- 5.1.1 Government Institution
- 5.1.2 Private Sector
- 5.1.3 Other
- 5.2 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Application
- 5.2.1 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Multivalent Oral Rotavirus Vaccine Sales Volume by Application (2020-2031)
- 5.2.3 Global Multivalent Oral Rotavirus Vaccine Sales Volume Share by Application (2020-2031)
- 5.3 Global Multivalent Oral Rotavirus Vaccine Sales Value by Application
- 5.3.1 Global Multivalent Oral Rotavirus Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Multivalent Oral Rotavirus Vaccine Sales Value by Application (2020-2031)
- 5.3.3 Global Multivalent Oral Rotavirus Vaccine Sales Value Share by Application (2020-2031)
- 6 Multivalent Oral Rotavirus Vaccine Regional Sales and Value Analysis
- 6.1 Global Multivalent Oral Rotavirus Vaccine Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Multivalent Oral Rotavirus Vaccine Sales by Region (2020-2031)
- 6.2.1 Global Multivalent Oral Rotavirus Vaccine Sales by Region: 2020-2025
- 6.2.2 Global Multivalent Oral Rotavirus Vaccine Sales by Region (2026-2031)
- 6.3 Global Multivalent Oral Rotavirus Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Multivalent Oral Rotavirus Vaccine Sales Value by Region (2020-2031)
- 6.4.1 Global Multivalent Oral Rotavirus Vaccine Sales Value by Region: 2020-2025
- 6.4.2 Global Multivalent Oral Rotavirus Vaccine Sales Value by Region (2026-2031)
- 6.5 Global Multivalent Oral Rotavirus Vaccine Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 6.6.2 North America Multivalent Oral Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 6.7.2 Europe Multivalent Oral Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Multivalent Oral Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 6.9.2 South America Multivalent Oral Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Multivalent Oral Rotavirus Vaccine Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Multivalent Oral Rotavirus Vaccine Sales Value Share by Country, 2024 VS 2031
- 7 Multivalent Oral Rotavirus Vaccine Country-level Sales and Value Analysis
- 7.1 Global Multivalent Oral Rotavirus Vaccine Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Multivalent Oral Rotavirus Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Multivalent Oral Rotavirus Vaccine Sales by Country (2020-2031)
- 7.3.1 Global Multivalent Oral Rotavirus Vaccine Sales by Country (2020-2025)
- 7.3.2 Global Multivalent Oral Rotavirus Vaccine Sales by Country (2026-2031)
- 7.4 Global Multivalent Oral Rotavirus Vaccine Sales Value by Country (2020-2031)
- 7.4.1 Global Multivalent Oral Rotavirus Vaccine Sales Value by Country (2020-2025)
- 7.4.2 Global Multivalent Oral Rotavirus Vaccine Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.9.2 France Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.16.2 China Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.19.2 India Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Multivalent Oral Rotavirus Vaccine Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Multivalent Oral Rotavirus Vaccine Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Multivalent Oral Rotavirus Vaccine Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Serum Institute of India
- 8.1.1 Serum Institute of India Comapny Information
- 8.1.2 Serum Institute of India Business Overview
- 8.1.3 Serum Institute of India Multivalent Oral Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Serum Institute of India Multivalent Oral Rotavirus Vaccine Product Portfolio
- 8.1.5 Serum Institute of India Recent Developments
- 8.2 Lanzhou Institute of Biological Products
- 8.2.1 Lanzhou Institute of Biological Products Comapny Information
- 8.2.2 Lanzhou Institute of Biological Products Business Overview
- 8.2.3 Lanzhou Institute of Biological Products Multivalent Oral Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Lanzhou Institute of Biological Products Multivalent Oral Rotavirus Vaccine Product Portfolio
- 8.2.5 Lanzhou Institute of Biological Products Recent Developments
- 8.3 Merck
- 8.3.1 Merck Comapny Information
- 8.3.2 Merck Business Overview
- 8.3.3 Merck Multivalent Oral Rotavirus Vaccine Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Merck Multivalent Oral Rotavirus Vaccine Product Portfolio
- 8.3.5 Merck Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Multivalent Oral Rotavirus Vaccine Value Chain Analysis
- 9.1.1 Multivalent Oral Rotavirus Vaccine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Multivalent Oral Rotavirus Vaccine Sales Mode & Process
- 9.2 Multivalent Oral Rotavirus Vaccine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Multivalent Oral Rotavirus Vaccine Distributors
- 9.2.3 Multivalent Oral Rotavirus Vaccine Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.